Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
- Hementerin80 kDa
- Hementin80 kDa
- Hementin-Like Protein (HLP-1)80 kDa
- Leech Collagenase70 kDa
- Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
- Leech Apyrase67 kDa
- Calin65 kDa
- Hyaluronidase60 kDa
- Antithrombin III binding protein58 kDa
- Collagenolytic Fibrinolysin55 kDa
- Leech Thrombospondin-Like Protein50 kDa
- Hirudin7 kDa
Mechanistic Evidence Box
Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.- Page type
- Compound profile
- Evidence type
- Clinical and regulatory evidence (FDA-approved derived drug)
- Evidence level
- In vitro
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding · Allergy / anaphylaxis
Clinical translation limit
Hirudin's direct thrombin binding in vitro and in animal models does NOT establish therapeutic efficacy of whole medicinal-leech therapy for any indication outside FDA-cleared microsurgical flap salvage (K040187). Pharmaceutical use of natural hirudin is rare; FDA-approved recombinant analogs (lepirudin, desirudin) and the synthetic analog bivalirudin are separate drugs with their own clinical evidence base.

Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Tier A — FDA-approved derivative
- Molecular weight
- 7,000 Da
- Source species
- Hirudo medicinalis
- Discovered
- 1884 · John Berry Haycraft (University of Edinburgh)
- Derived FDA-approved drug
- Lepirudin (Refludan), Desirudin (Iprivask), Bivalirudin (Angiomax)
Biological Targets
- → thrombin (Factor IIa)
Key Citations
- Haycraft JB (1884), Proc R Soc Lond
- Markwardt F (1957), Hoppe-Seylers Z Physiol Chem
- Stone SR, Hofsteenge J (1986), Biochemistry · PMID 3768302
External Resources
Related Anticoagulant Compounds
Antistasin
Factor Xa inhibitor from the Mexican leech (1987) — used in early animal studies of factor Xa as a target; the DOAC drugs are synthetic and not derived from it.
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.
Hirudin-PA
Hirudin variant from Hirudinaria manillensis with distinct kinetics.